SCHEMBL9909158

SCHEMBL9909158

N#Cc1ccccc1-c1nccc2ccc(C(=O)O)cc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
F10 P00742 1/20 0.46
PLAU P00749 1/20 0.46
AURKA O14965 1/20 0.42
SLC22A12 Q96S37 1/20 0.42
SYK P43405 1/20 0.41
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
F2 P00734 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2C Q14957 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909154 0.86 F10 (0.48) KMT2AKDM4EMAPTMAPK1F10
SCHEMBL9909159 0.84 PLAU (0.43) KDM4EPLAUSLC22A12RAB9AKDM4C
SCHEMBL9909261 0.84 HTR5A (0.49) KMT2AKDM4EMAPTMAPK1F10
SCHEMBL16502684 0.82 PLAU (0.50) KMT2AKDM4EMAPTPLAUMEN1
SCHEMBL16509458 0.81 SLC22A12 (0.44) KMT2AKDM4EMAPTMAPK1PLAU
SCHEMBL16502465 0.80 SLC22A12 (0.46) SLC22A12GRIN2DGRIN2AGRIN2C
SCHEMBL9909203 0.79 ALDH1A1 (0.41) MAPK1F10AURKASLC22A12SYK
SCHEMBL9907335 0.78 PLAU (0.55) KDM4EMAPTPLAURAB9AF2
SCHEMBL9907384 0.78 PLAU (0.46) KMT2AKDM4EMAPTPLAUMEN1
SCHEMBL9909227 0.77 SLC22A12 (0.47) PLAUSLC22A12KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E KMT2A 1729/4885KDM4E 1474/4885MAPT 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.